Clinical Comparison of CHOP Plus Oral VP-16 Regimen and CHOP Regimen for Adverse Prognostic Factor Non-Hodgkin's Lymphoma

Objective Comparison the clinical results of CHOP plus oral VP-16 regimen and standard CHOP regimen for the treatment of intermediate or high grade Non-Hodgkin's lymphoma(NHL) with adverse prognostic factor.Methods 72 cases of pathologically proved intermediate or high grade NHL patients in international prognostic index (IPI) high-intermediate risk and high risk groups were enrolled and randomly treated with CHOP regimen plus oral VP-16 capsule(intensive regimen group)or CHOP regimen(Standard regimen group).Results Complete response rates were (67.6%)(25/37) and (45.7%)(16/35), respectively. There were no statistically significant difference between the two groups (P(0.05)). But two-year OS and two-year DFS of intensive regimen group were (59.5%) (22/37) and (43.2%)(16/37), respectively. Superior over (34.3%) (12/35), 20.0(7/35) for standard regimen group (P(0.05)). About the side effects, leukopenia of intensive regimen was more serious than standard regimen (P(0.01)),especially for Ⅲ～Ⅳ leukopenia and thrombocytopenia(P0.01). and the incidence of related fever from leukopenia of intensive regimen was higher than standard regimen too (χ~2=(4.66),P(0.05)). The relative dose intensity of two groups was (93.7%) and 96.6%, respectively.Conclusion CHOP plus oral VP-16 intensive regimen had superior therapeutic efficacy over standard CHOP regimen for intermediate or high grade Non-Hodgkin's lymphoma(NHL) with adverse prognostic factor and was feasible in clinical status.